Entero Healthcare Solutions promoters declare no encumbrance on shares for FY26

Promoters of Entero Healthcare Solutions Limited , including Prem Sethi, Prabhat Agrawal, and OrbiMed Asia III Mauritius Limited, have declared that no encumbrance was created on the company's shares during the financial year ended March 31, 2026. The disclosures confirm that neither the promoters nor persons acting in concert with them established any direct or indirect charges on the shares throughout FY26.

The declarations were submitted to BSE Limited and the National Stock Exchange of India Limited in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation mandates annual disclosures by promoters to ensure transparency regarding any pledges or charges on their holdings.

Key Filing Details

Detail	Information
Promoter Name	Prem Sethi, Prabhat Agrawal, OrbiMed Asia III Mauritius Limited
Regulation	Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Financial Year	FY26 (ended March 31, 2026)
Encumbrance Status	No encumbrance created

The documents confirm that the promoters' shareholding remains free from pledges or other charges for the reported period.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.47%	+6.40%	-12.85%	+22.61%	+3.70%	+2.68%

Entero Healthcare Solutions Limited reported a 36% year-on-year increase in profit after tax (PAT) to ₹146 crore for the financial year ended March 31, 2026, driven by robust operational performance and strategic acquisitions. Revenue from operations for FY26 grew by 31.5% on a like-for-like basis to ₹6,591 crore, while EBITDA improved to ₹266 crore with a margin expansion of 67 basis points to 4%. The company’s operating cash flow for the year stood at ₹96.2 crore, a significant turnaround from the previous year. The company released the transcript of the earnings call held on May 26, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Q4 & FY26 Financial Highlights

Entero Healthcare delivered significant improvement across key financial metrics during the quarter and full year. The consolidated net profit for Q4FY26 stood at ₹45.1 crore, compared to the corresponding period of the previous year. EBITDA for the quarter increased to ₹86 crore, with the EBITDA margin expanding to 4.5%.

Metric	Q4FY26	Q4FY25	YoY Growth
Revenue (₹ Cr)	1,909.9	1,339.1	42.6%
EBITDA (₹ Cr)	86	N/A	76%
Net Profit (₹ Cr)	45.1	N/A	44%

For the full year FY26, revenue grew by 31.5% to ₹6,591 crore. The company achieved an EBITDA margin of 4%, up from 3.33% in FY25, and reported a net profit after tax of ₹146 crore. The operating cash flow for FY26 was recorded at ₹96.2 crore.

Operational and Strategic Updates

The company outperformed market growth, recording an organic growth of 15.6% against the industry IPM growth of 10% in FY26. Entero expanded its operational reach, covering 523 districts and serving over 100,000 retail customers. The company completed seven acquisitions during the year, including Sai RK Pharma Pvt Ltd and Ace Cardiopathy Solutions Pvt Ltd, to strengthen its presence in specialty pharma and MedTech segments. The MedTech segment now contributes more than ₹1,000 crore in annualized revenue.

FY27 Guidance and Outlook

Management provided guidance for FY27, targeting consolidated revenue growth of 23% year-on-year, excluding any new acquisitions. The company aims to achieve an EBITDA margin of 5%, driven by profitable revenue growth and operational efficiencies. Entero intends to maintain an EBITDA to operating cash flow conversion ratio of at least 50%. The MedTech segment is expected to contribute more than 15% to revenue, with potential to reach 20% in 2-3 years. The company expects the tax rate to be in the range of 22%-23% for FY27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE010601016/d7bae6c07be64939.pdf